Assetmark Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 461,137 shares of the biopharmaceutical company’s stock after buying an additional 12,520 shares during the period. Assetmark Inc.’s holdings in Gilead Sciences were worth $35,604,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Resource Management LLC increased its position in shares of Gilead Sciences by 6.7% in the 2nd quarter. Resource Management LLC now owns 10,688 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 674 shares during the last quarter. Stralem & Co. Inc. increased its position in shares of Gilead Sciences by 8.0% in the 3rd quarter. Stralem & Co. Inc. now owns 9,400 shares of the biopharmaceutical company’s stock worth $726,000 after purchasing an additional 700 shares during the last quarter. Silverleafe Capital Partners LLC increased its position in shares of Gilead Sciences by 17.4% in the 3rd quarter. Silverleafe Capital Partners LLC now owns 4,719 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 701 shares during the last quarter. Reilly Financial Advisors LLC increased its position in shares of Gilead Sciences by 98.3% in the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 704 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS increased its position in shares of Gilead Sciences by 0.4% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 174,000 shares of the biopharmaceutical company’s stock worth $12,326,000 after purchasing an additional 710 shares during the last quarter. 78.19% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:GILD opened at $69.55 on Thursday. The company has a quick ratio of 3.37, a current ratio of 3.45 and a debt-to-equity ratio of 1.09. Gilead Sciences, Inc. has a fifty-two week low of $64.27 and a fifty-two week high of $89.54. The stock has a market cap of $93.06 billion, a P/E ratio of 8.13, a price-to-earnings-growth ratio of -2.75 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The business had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter in the prior year, the firm earned $2.27 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 6.44 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s dividend payout ratio is presently 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $69.55, for a total transaction of $3,477,500.00. Following the completion of the sale, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $213,362,847.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 150,000 shares of company stock valued at $10,939,500. Insiders own 1.16% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. Oppenheimer reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, November 14th. Finally, Raymond James reissued a “buy” rating on shares of Gilead Sciences in a research report on Thursday, November 1st. Eleven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $88.63.

ILLEGAL ACTIVITY WARNING: “Assetmark Inc. Has $35.60 Million Position in Gilead Sciences, Inc. (GILD)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/assetmark-inc-has-35-60-million-position-in-gilead-sciences-inc-gild/2663817.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Read More: Understanding Analyst Ratings

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.